Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

There is a paucity of information about molecularly driven therapy in osteosarcomas. We report a 31-year-old woman with chemotherapy–refractory metastatic osteosarcoma who was successfully treated with the combination of palbociclib (CDK4/6 inhibitor) and lenvatinib (multikinase FGFR inhibitor), sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Persha, Hanna E., Kato, Shumei, De, Pradip, Adashek, Jacob J., Sicklick, Jason K., Subbiah, Vivek, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420268/
https://www.ncbi.nlm.nih.gov/pubmed/36031605
http://dx.doi.org/10.1186/s13045-022-01344-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420268/
https://www.ncbi.nlm.nih.gov/pubmed/36031605
http://dx.doi.org/10.1186/s13045-022-01344-x

Ejemplares similares